Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -34.04% is in line with its 5-year average of -37.10%, around the middle of its 5-year range (-58.35%–15.64%).
65.36% below its 12-month average of -20.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.92%.
RETURN ON ASSETS (ROA)
-34.04%
RETURN ON ASSETS (ROA) AVG TTM
-20.59%
RETURN ON ASSETS (ROA) AVG 3Y
-37.88%
RETURN ON ASSETS (ROA) AVG 5Y
-37.10%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-65.36%
CURRENT VS 3Y AVG
+10.13%
CURRENT VS 5Y AVG
+8.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-5.58%
vs the sector median at left
Black Diamond Therapeutics, Inc.
Market Cap
$103.14M
Return on Assets (ROA)
-34.04%
TTM Avg
-20.59%
3Y Avg
-37.88%
5Y Avg
-37.10%
Market Cap
$102.75M
Return on Assets (ROA)
-69.14%
TTM Avg
-63.05%
3Y Avg
-52.31%
5Y Avg
-58.69%
Market Cap
$104.26M
Return on Assets (ROA)
-33.85%
TTM Avg
-28.41%
3Y Avg
-17.06%
5Y Avg
-12.28%
Market Cap
$104.68M
Return on Assets (ROA)
-57.98%
TTM Avg
-386.38%
3Y Avg
-312.00%
5Y Avg
-312.00%
Market Cap
$101.36M
Return on Assets (ROA)
7.36%
TTM Avg
-1.10%
3Y Avg
-3.18%
5Y Avg
2.66%
Market Cap
$106.52M
Return on Assets (ROA)
-70.09%
TTM Avg
-324.97%
3Y Avg
-229.15%
5Y Avg
-168.27%
Market Cap
$99.62M
Return on Assets (ROA)
-32.73%
TTM Avg
-70.83%
3Y Avg
-106.23%
5Y Avg
-81.00%
Market Cap
$106.93M
Return on Assets (ROA)
-63.19%
TTM Avg
-62.03%
3Y Avg
-51.81%
5Y Avg
-103.22%
Market Cap
$106.96M
Return on Assets (ROA)
-233.43%
TTM Avg
-298.69%
3Y Avg
-252.88%
5Y Avg
-237.20%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | $103.14M | -34.04% | -20.59% | -37.88% | -37.10% |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.75M | -69.14% | -63.05% | -52.31% | -58.69% |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | -33.85% | -28.41% | -17.06% | -12.28% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | -57.98% | -386.38% | -312.00% | -312.00% |
| The Joint Corp. (JYNT)vs › | $101.36M | 7.36% | -1.10% | -3.18% | 2.66% |
| Immunic, Inc. (IMUX)vs › | $106.52M | -70.09% | -324.97% | -229.15% | -168.27% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $99.62M | -32.73% | -70.83% | -106.23% | -81.00% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | -63.19% | -62.03% | -51.81% | -103.22% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | -233.43% | -298.69% | -252.88% | -237.20% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | -16.87% | -6.13% | -6.48% | -5.59% |
ROA
-34.0%
ROE
-44.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 15.64% |
| 2024-12-31 | -56.81% |
| 2023-12-31 | -51.99% |
| 2022-12-31 | -58.35% |
| 2021-12-31 | -50.71% |
| 2020-12-31 | -20.40% |
| 2019-12-31 | -22.27% |
| 2018-12-31 | -17.23% |
| 2017-12-31 | -57.37% |
